Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 3

Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

NCT07717892 · tracked via the Priya Life Science USA tracker
Phase
Phase 3
Started
2026-06-25
Last updated
2026-11-06

Condition(s) studied

ADHD

Investigational drug(s) / intervention(s)

Solriamfetol Dose A →Solriamfetol Dose B →Placebo

Solriamfetol Dose A: Solriamfetol capsules, taken once daily

Solriamfetol Dose B: Solriamfetol capsules, taken once daily

Placebo: Placebo capsules, taken once daily

Study summary

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.

Eligibility

Sex
ALL
Min age
12 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female, aged 12 to \<18 years. * Primary diagnosis of ADHD according to DSM-5 criteria. * Has parents/legal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures. Exclusion Criteria: * Unable to comply with study procedures. * Medically inappropriate for study participation in the opinion of the investigator.

Primary outcome measure(s)

  • ADHD-RS-5 Total Score, Change from Baseline to Week 6 — 6 weeks
    Attention Deficit/ Hyperactivity Disorder Rating Scale-5, Interview with Informant, Adolescent Version (ADHD-RS-5)

Trial sites (31)

FacilityCityRegionStatus
Clinical Research Site Dothan Alabama Recruiting
Clinical Research Site Little Rock Arkansas Recruiting
Clinical Research Site Anaheim California Recruiting
Clinical Research Site Irvine California Recruiting
Clinical Research Site Long Beach California Recruiting
Clinical Research Site Los Angeles California Recruiting
Clinical Research Site Walnut Creek California Recruiting
Clinical Research Site Coral Gables Florida Recruiting
Clinical Research Site Gainesville Florida Recruiting
Clinical Research Site Jacksonville Florida Recruiting
Clinical Research Site Maitland Florida Recruiting
Clinical Research Site Orlando Florida Recruiting
Clinical Research Site Orlando Florida Recruiting
Clinical Research Site Atlanta Georgia Recruiting
Clinical Research Site Bardstown Kentucky Recruiting
Clinical Research Site Owensboro Kentucky Recruiting
Clinical Research Site Springfield Massachusetts Recruiting
Clinical Research Site Worcester Massachusetts Recruiting
Clinical Research Site Jackson Mississippi Recruiting
Clinical Research Site Las Vegas Nevada Recruiting
Clinical Research Site Staten Island New York Recruiting
Clinical Research Site Portland Oregon Recruiting
Clinical Research Site North Charleston South Carolina Recruiting
Clinical Research Site Memphis Tennessee Recruiting
Clinical Research Site Austin Texas Recruiting
Clinical Research Site Friendswood Texas Recruiting
Clinical Research Site San Antonio Texas Recruiting
Clinical Research Site Provo Utah Recruiting
Clinical Research Site Fairfax Virginia Recruiting
Clinical Research Site Petersburg Virginia Recruiting
Clinical Research Site Everett Washington Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07717892 on ClinicalTrials.gov ↗ ← All trials in the USA